Skip to main content
KLRA
NASDAQ Life Sciences

Kailera's Oral GLP-1 KAI-7535 Achieves Up to 10.9% Weight Loss in Phase 3 Obesity Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$23.97
Mkt Cap
$3.019B
52W Low
$18.5
52W High
$28.227
52W Position info
30% above low
Off High info
15% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

KLRA sits 30% above its 52-week low of $18.5.

Summary

Kailera Therapeutics announced strong positive topline Phase 3 data for its oral GLP-1 receptor agonist, KAI-7535, in both obesity and Type 2 Diabetes, with the drug meeting the main goal of late-stage trials in China. In the HARBOR-1 obesity trial, patients achieved a mean weight loss of up to 10.9% from baseline at Week 44, significantly outperforming placebo. This success provides concrete validation for a key asset in the highly competitive GLP-1 market, following the company's recent IPO and general positive pipeline updates. The efficacy demonstrated is competitive for an oral GLP-1, positioning KAI-7535 as a potential significant player. Kailera is also conducting a global Phase 2 trial for KAI-7535, with data expected in 2027.

At the time of this announcement, KLRA was trading at $23.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $18.50 to $28.23. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

KLRA - Latest Insights

KLRA
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.74
Real-time Price: $12.12 info
Change: -$0.620 (-5%) info
Market Cap: $1.592B info
KLRA
Oct 01, 2026, 6:45 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.20
Real-time Price: $12.12 info
Change: +$0.920 (+8%) info
Market Cap: $1.592B info
KLRA
Aug 12, 2026, 4:29 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.20
Real-time Price: $12.12 info
Change: -$6.08 (-33%) info
Market Cap: $1.592B info
KLRA
Aug 12, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.59
Real-time Price: $12.12 info
Change: -$6.47 (-35%) info
Market Cap: $1.592B info
KLRA
Jun 05, 2026, 7:40 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $19.37
Real-time Price: $12.12 info
Change: -$7.25 (-37%) info
Market Cap: $1.592B info